Quantitative analysis of diagnostic guidelines for HER2-status assessment

Journal of Molecular Diagnostics

Volumn 14, Issue 3, 2012, Pages 199-205

  Stenzinger, Albrecht ^a   Von Winterfeld, Moritz ^b   Aulmann, Sebastian ^a   Warth, Arne ^a   Weichert, Wilko ^a   Denkert, Carsten ^b   Rschoff, Josef ^c   Dietel, Manfred ^b   Klauschen, Frederick ^b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Pathologie Nordhessen and TARGOS Molecular Pathology GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CANCER; CENTROMERE; DATA ANALYSIS; GENE AMPLIFICATION; GENE DOSAGE; IN SITU HYBRIDIZATION; MONTE CARLO METHOD; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; SIMULATION; STOMACH CANCER;

BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; IN SITU HYBRIDIZATION; IN SITU HYBRIDIZATION, FLUORESCENCE; MOLECULAR DIAGNOSTIC TECHNIQUES; MONTE CARLO METHOD; PRACTICE GUIDELINES AS TOPIC; RECEPTOR, ERBB-2; SAMPLE SIZE; STOMACH NEOPLASMS;

ALIAS;

EID: 84859591581     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2012.01.012     Document Type: Article

References (26)

1. R. Mehta, R.K. Jain, S. Badve Personalized medicine: the road ahead Clin Breast Cancer 11 2011 20 26
2. C.R. King, M.H. Kraus, S.A. Aaronson Amplification of a novel v-erbB-related gene in a human mammary carcinoma Science 229 1985 -976
3. D.J. Slamon, W. Godolphin, L.A. Jones, J.A. Holt, S.G. Wong, D.E. Keith, W.J. Levin, S.G. Stuart, J. Udove, A. Ullrich, M. Press Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 1989 707 712
4. W. Hanna Testing for HER2 status Oncology 61 Suppl 2 2001 22 30
5. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, W.L. McGuire Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
6. Y. Bang, H. Chung, J. Xu, F. Lordick, A. Sawaki, O. Lipatov, C. See, J. Rueschoff, E. Van Cutsem Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial J Clin Oncol 27 2009 15s
7. Y.J. Bang, E. Van Cutsem, A. Feyereislova, H.C. Chung, L. Shen, A. Sawaki, F. Lordick, A. Ohtsu, Y. Omuro, T. Satoh, G. Aprile, E. Kulikov, J. Hill, M. Lehle, J. Rschoff, Y.K. Kang ToGA Trial Investigators Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 2010 687 697
8. J. Ruschoff, I. Nagelmeier, G. Baretton, M. Dietel, H. Hofler, H.U. Schildhaus, R. Bttner, W. Schlake, O. Stoss, H.H. Kreipe [HER2 testing in gastric cancer. What is different in comparison to breast cancer?] German Pathologe 31 2010 208 217
9. M. Hofmann, O. Stoss, D. Shi, R. Buttner, M. van de Vijver, W. Kim, A. Ochiai, J. Rschoff, T. Henkel Assessment of a HER2 scoring system for gastric cancer: results from a validation study Histopathology 52 2008 797 805
10. J. Ruschoff, M. Dietel, G. Baretton, S. Arbogast, A. Walch, G. Monges, M.P. Chenard, F. Penault-Llorca, I. Nagelmeier, W. Schlake, H. Hfler, H.H. Kreipe HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing Virchows Arch 457 2010 299 307
11. A.C. Wolff, M.E. Hammond, J.N. Schwartz, K.L. Hagerty, D.C. Allred, R.J. Cote, M. Dowsett, P.L. Fitzgibbons, W.M. Hanna, A. Langer, L.M. McShane, S. Paik, M.D. Pegram, E.A. Perez, M.F. Press, A. Rhodes, C. Sturgeon, S.E. Taube, R. Tubbs, G.H. Vance, M. van de Vijver, T.M. Wheeler, D.F. Hayes American Society of Clinical Oncology/College of American Pathologists American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer Arch Pathol Lab Med 131 2007 18 43
12. M.J. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith, L. Gianni, J. Baselga, R. Bell, C. Jackisch, D. Cameron, M. Dowsett, C.H. Barrios, G. Steger, C.S. Huang, M. Andersson, M. Inbar, M. Lichinitser, I. Lng, U. Nitz, H. Iwata, C. Thomssen, C. Lohrisch, T.M. Suter, J. Rschoff, T. Suto, V. Greatorex, C. Ward, C. Straehle, E. McFadden, M.S. Dolci, R.D. Gelber Herceptin Adjuvant (HERA) Trial Study Team Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 2005 1659 1672
13. E.H. Romond, E.A. Perez, J. Bryant, V.J. Suman, C.E. Geyer Jr., N.E. Davidson, E. Tan-Chiu, S. Martino, S. Paik, P.A. Kaufman, S.M. Swain, T.M. Pisansky, L. Fehrenbacher, L.A. Kutteh, V.G. Vogel, D.W. Visscher, G. Yothers, R.B. Jenkins, A.M. Brown, S.R. Dakhil, E.P. Mamounas, W.L. Lingle, P.M. Klein, J.N. Ingle, N. Wolmark Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 2005 1673 1684
14. D.L. Persons, R.R. Tubbs, L.D. Cooley, G.W. Dewald, P.K. Dowling, E. Du, J.T. Mascarello, K.W. Rao, K.S. Wilson, D.J. Wolff, G. Habegger-Vance HER-2 fluorescence in situ hybridization: results from the survey program of the College of American Pathologists Arch Pathol Lab Med 130 2006 325 331
15. G. Viale, M.G. Mastropasqua What can the pathologist offer for optimal treatment choice? Ann Oncol 21 Suppl 7 2010 vii27 vii29
16. E.A. Perez, V.J. Suman, N.E. Davidson, S. Martino, P.A. Kaufman, W.L. Lingle, P.J. e Flynn, J.N. Ingle, D. Visscher, R.B. Jenkins HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial J Clin Oncol 24 2006 3032 3038
17. I. Smith, M. Procter, R.D. Gelber, S. Guillaume, A. Feyereislova, M. Dowsett, A. Goldhirsch, M. Untch, G. Mariani, J. Baselga, M. Kaufmann, D. Cameron, R. Bell, J. Bergh, R. Coleman, A. Wardley, N. Harbeck, R.I. Lopez, P. Mallmann, K. Gelmon, N. Wilcken, E. Wist, P. Snchez Rovira, M.J. Piccart-Gebhart HERA study team 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 369 2007 29 36
18. E. Tan-Chiu, G. Yothers, E. Romond, C.E. Geyer Jr, M. Ewer, D. Keefe, R.P. Shannon, S.M. Swain, A. Brown, L. Fehrenbacher, V.G. Vogel, T.E. Seay, P. Rastogi, E.P. Mamounas, N. Wolmark, J. Bryant Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: nSABP B-31 J Clin Oncol 23 2005 7811 7819
19. G.A. Viani, S.L. Afonso, E.J. Stefano, L.I. De Fendi, F.V. Soares Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials BMC Cancer 7 2007 153
20. R.A. Walker, J.M. Bartlett, M. Dowsett, I.O. Ellis, A.M. Hanby, B. Jasani, K. Miller, S.E. Pinder HER2 testing in the UK: further update to recommendations J Clin Pathol 61 2008 818 824
21. F. Penault-Llorca, M. Bilous, M. Dowsett, W. Hanna, R.Y. Osamura, J. Ruschoff, M. van de Vijver Emerging technologies for assessing HER2 amplification Am J Clin Pathol 132 2009 539 548
22. M. Dowsett, W.M. Hanna, M. Kockx, F. Penault-Llorca, J. Ruschoff, T. Gutjahr, K. Habben, M.J. van de Vijver Standardization of HER2 testing: results of an international proficiency-testing ring study Mod Pathol 20 2007 584 591
23. S. Paik, J. Bryant, E. Tan-Chiu, E. Romond, W. Hiller, K. Park, A. Brown, G. Yothers, S. Anderson, R. Smith, D.L. Wickerham, N. Wolmark Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience J Natl Cancer Inst 94 2002 852 854
24. P.C. Roche, V.J. Suman, R.B. Jenkins, N.E. Davidson, S. Martino, P.A. Kaufman, F.K. Addo, B. Murphy, J.N. Ingle, E.A. Perez Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831 J Natl Cancer Inst 94 2002 855 857
25. J.M. Striebel, R. Bhargava, C. Horbinski, U. Surti, D.J. Dabbs The equivocally amplified HER2 FISH result on breast core biopsy: indications for further sampling do affect patient management Am J Clin Pathol 129 2008 383 390
26. I. Vanden Bempt, P. Van Loo, M. Drijkoningen, P. Neven, A. Smeets, M.R. Christiaens, R. Paridaens, C. De Wolf-Peeters Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing J Clin Oncol 26 2008 4869 4874